SEC Form 4 · accession 0001140361-17-041187
SUNESIS PHARMACEUTICALS INC · SNSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Nov 2, 2017
Accepted (ET)
Nov 6, 2017 · 9:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001061027
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 2, 2017 | P | 25,300 | $2.59 | A | 3,275,300 | I | See Footnote |
| Common StockF1 | Nov 3, 2017 | P | 40,000 | $2.89 | A | 3,315,300 | I | See Footnote |
| Common StockF1 | Nov 6, 2017 | P | 16,200 | $2.77 | A | 3,331,500 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology.